EFPIA Partners in Research address the need for quality technology integration in pre-competitive collaborations

The evolving societal and healthcare challenges as well as opportunities offered by new sciences and technologies, call for a much more integrated health research environment than in the past. EFPIA created "Partners in Research" as a constituent entity open to companies operating in associated sectors (such as imaging, MedTech, diagnostics, animal health, IT including e- and m-technologies, contract research organisations, etc.), and aiming to participate to collaborative research partnerships. This membership status made it possible to jointly design and implement collaborative R&D initiatives in the framework of the Innovative Medicines Initiative (the largest public private partnership in health research worldwide), which ultimately implemented new R&D, operational and business models that benefit all sectors involved (impact on R&D processes), patients (new treatment pathways), and society (incentives for reinvestment in areas where there is market failure).

Meanwhile science is driving new avenues of research and development often spanning different sectors within the life-science community, and it is clear that future breakthroughs in medical science will involve cross-sectoral discoveries, such as medical device / drug combinations or diagnostics based on artificial intelligence. With the end of the IMI2 programme in sight, and aware of the growing importance of cross-sectoral cooperation, Innovative Health Initiative (IHI), a new public private partnership was launched in 2021.

IHI will leverage the benefits of cross-sectoral collaborations (pharma, biotech, vaccines, device and diagnostics) in research and innovation to better respond to current and emerging health needs.

Companies wishing to join an IHI project, but which do not qualify to join other founding IHI trade associations (with EuropaBio, Medtech Europe and COCIR) can apply for the EFPIA Partner in Research membership.

What’s the investment?

- A single entry membership fee of €5,000 (for more details, please email science-policy@efpia.eu)
- In kind or cash contribution to IMI and/or IHI projects or contribution to the deployment, upscaling, dissemination of IMI results – the selection of projects/activities and level of investment is up for decision of each company based on their interest and capabilities.
- Appointment of a contact person that will liaise with EFPIA and facilitate access to relevant Partner in Research departments and their involvement in EFPIA/IHI activities.

What’s in it for you?

IMI and IHI projects offer a perfect safe harbour environment to develop and test new approaches to integration of pharma and non-pharma technologies and tools. Your company contribution to IHI projects is matched by IHI funding for non-profit beneficiaries (academics, SMEs, patients, etc.). In addition, the Partners in Research membership offers the possibility to jointly develop new integrated business models as well as:

- Shaping the IHI strategies and projects to your company core activity and pipelines
- Participation in IMI/IHI consortia where your assets (tools, methodologies, etc.) can be improved and validated in real life R&D in several companies simultaneously
- Access to cohorts, data and know how not available in standard research collaborations
- Networking and access to the pharmaceutical collaborative ecosystem (large number of pharmaceutical companies)
- Support and advise on IHI operational matters